What is claimed is :

1. A method of treating a disease chosen from the group consisting of psoriasis, ulcers, gastroesophageal reflux and conditions caused by or contributed to by gastric hypersecretion, said method comprising administering to a human a therapeutically effective amount of hydroxylansoprazole or a pharmaceutically acceptable salt thereof.

2. A method according to claim 1 of treating ulcers which comprises administering to a human a therapeutically effective amount of hydroxylansoprazole or a pharmaceutically acceptable salt thereof.

3. A method according to claim 1 of treating gastroesophageal reflux disease which comprises administering to a human a therapeutically effective amount of hydroxylansoprazole or a pharmaceutically acceptable salt thereof.

4. A method according to claim 1 of treating a condition caused by or contributed to by gastric hypersecretion which comprises administering to a human a therapeutically effective amount of hydroxylansoprazole or a pharmaceutically acceptable salt thereof.

5. The method according to claim 4 wherein said condition is Zollinger-Ellison Syndrome.

6. A method according to claim 1 of treating psoriasis which comprises administering to a human a therapeutically effective amount of hydroxylansoprazole or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 wherein racemic hydroxylansoprazole is administered.

8. The method of claim 7 wherein the amount of racemic hydroxylansoprazole or a pharmaceutically acceptable salt thereof administered is from about 50 mg to about 1500 mg per day.

9. The method of claim 7 wherein racemic hydroxylansoprazole is administered orally.

10. The method of claim 1 wherein optically pure (+)-hydroxylansoprazole is administered.

11. The method of claim 10 wherein the amount of (+)-hydroxylansoprazole or a pharmaceutically acceptable salt thereof administered is from about 50 mg to about 1000 mg per day.

12. The method of claim 10 wherein optically pure (+)-hydroxylansoprazole is administered orally.

13. The method of claim 1 wherein optically pure (-)-hydroxylansoprazole is administered.

14. The method of claim 13 wherein the amount of (-)-hydroxylansoprazole or a pharmaceutically acceptable salt thereof administered is from about 50 mg to about 1000 mg per day.

15. The method of claim 13 wherein optically pure (-)-hydroxylansoprazole is administered orally.